Stephen B Williams1, Jinhai Huo2, Christopher D Kosarek3, Karim Chamie4, Selwyn O Rogers5, Michele A Williams6, Sharon H Giordano2, Simon P Kim7, Ashish M Kamat8. 1. The Division of Urology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA. stbwilli@utmb.edu. 2. The Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA. 3. The Division of Urology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA. 4. Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 5. Department of Surgery, The University of Chicago, Chicago, IL, USA. 6. School of Public Health, Washington University, St. Louis, MO, USA. 7. Department of Urology, Case Western Reserve Medical Center, Cleveland, OH, USA. 8. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
PURPOSE: Radical cystectomy is a surgical treatment for recurrent non-muscle-invasive and muscle-invasive bladder cancer; however, many patients may not receive this treatment. METHODS: A total of 27,578 patients diagnosed with clinical stage I-IV bladder cancer from 1 January 2007 to 31 December 2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) registry database. We used multivariable regression analyses to identify factors predicting the use of radical cystectomy and pelvic lymph node dissection. Cox proportional hazards models were used to analyze survival outcomes. RESULTS: A total of 1,693 (6.1%) patients with bladder cancer underwent radical cystectomy. Most patients (92.4%) who underwent radical cystectomy also underwent pelvic lymph node dissection. When compared with white patients, non-Hispanic blacks were less likely to undergo a radical cystectomy [odds ratio (OR) 0.79, 95% confidence interval (CI) 0.64-0.96, p = 0.019]. Moreover, recent year of surgery 2013 versus 2007 (OR 2.32, 95% CI 1.90-2.83, p < 0.001), greater percentage of college education ≥36.3 versus <21.3% (OR 1.23, 95% CI 1.04-1.44, p = 0.013), Midwest versus West (OR 1.64, 95% CI 1.39-1.94, p < 0.001), and more advanced clinical stage III versus I (OR 29.1, 95% CI 23.9-35.3, p < 0.001) were associated with increased use of radical cystectomy. Overall survival was improved for patients who underwent radical cystectomy compared with those who did not undergo a radical cystectomy (hazard ratio 0.88, 95% CI 0.80-0.97, p = 0.008). CONCLUSION: There is significant underutilization of radical cystectomy in patients across all age groups diagnosed with bladder cancer, especially among older, non-Hispanic black patients.
PURPOSE: Radical cystectomy is a surgical treatment for recurrent non-muscle-invasive and muscle-invasive bladder cancer; however, many patients may not receive this treatment. METHODS: A total of 27,578 patients diagnosed with clinical stage I-IV bladder cancer from 1 January 2007 to 31 December 2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) registry database. We used multivariable regression analyses to identify factors predicting the use of radical cystectomy and pelvic lymph node dissection. Cox proportional hazards models were used to analyze survival outcomes. RESULTS: A total of 1,693 (6.1%) patients with bladder cancer underwent radical cystectomy. Most patients (92.4%) who underwent radical cystectomy also underwent pelvic lymph node dissection. When compared with white patients, non-Hispanic blacks were less likely to undergo a radical cystectomy [odds ratio (OR) 0.79, 95% confidence interval (CI) 0.64-0.96, p = 0.019]. Moreover, recent year of surgery 2013 versus 2007 (OR 2.32, 95% CI 1.90-2.83, p < 0.001), greater percentage of college education ≥36.3 versus <21.3% (OR 1.23, 95% CI 1.04-1.44, p = 0.013), Midwest versus West (OR 1.64, 95% CI 1.39-1.94, p < 0.001), and more advanced clinical stage III versus I (OR 29.1, 95% CI 23.9-35.3, p < 0.001) were associated with increased use of radical cystectomy. Overall survival was improved for patients who underwent radical cystectomy compared with those who did not undergo a radical cystectomy (hazard ratio 0.88, 95% CI 0.80-0.97, p = 0.008). CONCLUSION: There is significant underutilization of radical cystectomy in patients across all age groups diagnosed with bladder cancer, especially among older, non-Hispanic black patients.
Authors: J P Stein; G Lieskovsky; R Cote; S Groshen; A C Feng; S Boyd; E Skinner; B Bochner; D Thangathurai; M Mikhail; D Raghavan; D G Skinner Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: Daniel A Barocas; Joann Alvarez; Tatsuki Koyama; Christopher B Anderson; Darryl T Gray; Jay H Fowke; Chaochen You; Sam S Chang; Michael S Cookson; Joseph A Smith; David F Penson Journal: Cancer Date: 2013-12-11 Impact factor: 6.860
Authors: Jeffrey J Leow; Stephen Reese; Quoc-Dien Trinh; Joaquim Bellmunt; Benjamin I Chung; Adam S Kibel; Steven L Chang Journal: BJU Int Date: 2015-01-26 Impact factor: 5.588
Authors: Pascal Zehnder; Urs E Studer; Eila C Skinner; George N Thalmann; Gus Miranda; Beat Roth; Jie Cai; Frédéric D Birkhäuser; Anirban P Mitra; Fiona C Burkhard; Ryan P Dorin; Siamak Daneshmand; Donald G Skinner; Inderbir S Gill Journal: BJU Int Date: 2013-07 Impact factor: 5.588
Authors: John L Gore; Mark S Litwin; Julie Lai; Elizabeth M Yano; Rodger Madison; Claude Setodji; John L Adams; Christopher S Saigal Journal: J Natl Cancer Inst Date: 2010-04-16 Impact factor: 13.506
Authors: Peter E Clark; Neeraj Agarwal; Matthew C Biagioli; Mario A Eisenberger; Richard E Greenberg; Harry W Herr; Brant A Inman; Deborah A Kuban; Timothy M Kuzel; Subodh M Lele; Jeff Michalski; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Jerome P Richie; Wade J Sexton; William U Shipley; Eric J Small; Philippe E Spiess; Donald L Trump; Geoffrey Wile; Timothy G Wilson; Mary Dwyer; Maria Ho Journal: J Natl Compr Canc Netw Date: 2013-04-01 Impact factor: 11.908
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Mohamed D Ray-Zack; Yong Shan; Hemalkumar B Mehta; Xiaoying Yu; Ashish M Kamat; Stephen B Williams Journal: Urol Oncol Date: 2018-11-13 Impact factor: 3.498
Authors: Elliott Freudenburg; Yong Shan; Ariza Martinez; Aditya Srinivasan; Giri Movva; Alexander Yu; Mohanad AlBayyaa; Zachary Klaassen; Stephen J Freedland; Ashish M Kamat; Stephen B Williams Journal: Cancer Causes Control Date: 2022-01-20 Impact factor: 2.506